Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

医学 偏头痛 安慰剂 物理疗法 相(物质) 双盲 物理医学与康复 麻醉 替代医学 病理 有机化学 化学
作者
Messoud Ashina,Michel Lantéri‐Minet,Patricia Pozo‐Rosich,Anders Ettrup,Cecilie Laurberg Christoffersen,Mette Krog Josiassen,Ravinder Phul,Bjørn Sperling
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:21 (7): 597-607 被引量:160
标识
DOI:10.1016/s1474-4422(22)00185-5
摘要

Background The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and acceptable safety and tolerability in phase 3 trials, but benefits in the subpopulations of patients with previous preventive treatment failures were not examined. We aimed to investigate the safety and efficacy of eptinezumab for migraine prevention in adults with migraine and two-to-four previous preventive treatment failures. Methods DELIVER was a multicentre, multi-arm, phase 3b trial comprising a 24-week double-blind, placebo-controlled period and a 48-week dose-blinded extension. We recruited adults with episodic or chronic migraine with at least 4 monthly migraine days (as per International Headache Society guidelines) and documented evidence of two-to-four previous preventive treatment failures within the past 10 years, from 96 study locations across Europe (n=93) and the USA (n=3). Patients were randomly assigned (1:1:1) via a centralised randomisation system, stratified by baseline monthly headache days and country, to eptinezumab 100 mg, eptinezumab 300 mg, or placebo. The primary efficacy endpoint was the change from baseline in mean monthly migraine days (captured using a daily electronic diary) in weeks 1–12, assessed in the full analysis set. All participants and study personnel were masked to study drug assignments. The dose-blinded extension period is ongoing. The trial is registered with ClinicalTrials.gov, NCT04418765, and EudraCT, 2019-004497-25. Findings Between June 1, 2020, and Oct 7, 2021, 891 individuals were randomly assigned and received at least one dose of study drug (safety population; eptinezumab 100 mg n=299 [34%], eptinezumab 300 mg n=294 [33%], placebo n=298 [33%]). 865 patients completed the placebo-controlled period. The change from baseline to weeks 1–12 in mean monthly migraine days was –4·8 (SE 0·37) with eptinezumab 100 mg, –5·3 (0·37) with eptinezumab 300 mg, and –2·1 (0·38) with placebo. The difference from placebo in change in mean monthly migraine days from baseline was significant with eptinezumab 100 mg (–2·7 [95% CI –3·4 to –2·0]; p<0·0001) and eptinezumab 300 mg (–3·2 [–3·9 to –2·5]; p<0·0001). Treatment-emergent adverse events occurred in 127 (42%) of 299 patients in the eptinezumab 100 mg group, in 120 (41%) of 294 in the eptinezumab 300 mg group, and in 119 (40%) of 298 in the placebo group. The most common treatment-emergent adverse event was COVID-19 (20 [7%] of 299 patients in the eptinezumab 100 mg group, 17 [6%] of 294 in the eptinezumab 300 mg group, and 16 [5%] of 298 in the placebo group). Serious adverse events were uncommon (five [2%] of 299 in the eptinezumab 100 mg group, seven [2%] of 294 in the eptinezumab 300 mg group, four [1%] of 298 in the placebo group) and included anaphylactic reaction (eptinezumab 300 mg n=2) and COVID-19 (eptinezumab 100 mg n=1 and eptinezumab 300 mg n=1). Interpretation In adults with migraine and two-to-four previous preventive treatment failures, eptinezumab provided significant migraine preventive effects compared with placebo, with acceptable safety and tolerability, indicating that eptinezumab might be an effective treatment option for this patient population. The dose-blinded extension period will provide additional long-term safety data in patients with migraine and previous preventive treatment failures. Funding H Lundbeck.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zsda完成签到,获得积分10
刚刚
刚刚
1秒前
homie发布了新的文献求助10
2秒前
呆萌尔风发布了新的文献求助20
2秒前
彭于晏的应助被zyyy采纳,获得30
2秒前
科研怪才完成签到,获得积分20
4秒前
小懒猪完成签到,获得积分10
4秒前
cc发布了新的文献求助10
4秒前
4秒前
科研通AI6.2的应助被phonon采纳,获得30
5秒前
鲸鱼完成签到,获得积分10
5秒前
6秒前
Hello的应助被Cope采纳,获得10
7秒前
ding的应助被Lachryz采纳,获得10
8秒前
8秒前
情怀的应助被窥荷采纳,获得10
9秒前
科研怪才发布了新的文献求助30
10秒前
余香的应助被最关心呈现出采纳,获得10
10秒前
糊涂小生007完成签到,获得积分10
10秒前
11秒前
Francis1213完成签到,获得积分10
11秒前
13秒前
老老实实好好活着完成签到,获得积分10
13秒前
13秒前
bkagyin的应助被Boubou采纳,获得10
14秒前
14秒前
15秒前
15秒前
zl完成签到,获得积分10
16秒前
段启瑞发布了新的文献求助20
16秒前
科研通AI6.4的应助被清辉影采纳,获得10
17秒前
18秒前
宁宁完成签到,获得积分10
18秒前
18秒前
18秒前
CTbnun发布了新的文献求助10
19秒前
Voyager发布了新的文献求助10
19秒前
one完成签到 ,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952